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Abstract
Purpose: To analyse the correlation between the fold change in residual liver volume (RLV) and residual liver uptake 
at 15 (RLU15) before and after percutaneous transhepatic portal vein embolisation (PTPE).
Material and methods: Between August 2010 and December 2016, 20 patients who underwent PTPE were retrospec-
tively selected. Before and three weeks after PTPE, contrast-enhanced computed tomography (CECT) and Tc-99m 
GSA scintigraphy were performed to analyse the fold changes in RLV and RLU15, respectively, as well as their 
correlation.
Results: After PTPE, a significant increase was observed in the RLV (before: 464 ± 99 ml; after: 573 ± 118 ml, p = 0.004) 
and the RLU15 (before: 11.0 ± 2.9%; after: 17.7 ± 3.8%, p = 5 × 10-7). The fold increase of RLV and RLU15 in all patients 
was 1.25 ± 0.15 and 1.66 ± 0.33, respectively. No significant correlation was observed in the fold increase in both 
RLV and RLU15 (r = 0.14, p = 0.66). In patients no. 3 and 9, who were outliers, the increase in RLV was minimal and 
RLU15 increased greatly, and these 2 patients underwent radical hepatectomy after PTPE.
Conclusions: No correlation was observed between the fold increase in RLV and RLU15 before and after PTPE. In 
order to accurately evaluate the residual liver function, it should be considered necessary to evaluate not only by 
morphological CECT volumetry, but also by functional outcome of Tc-99m GSA scintigraphy.
Residual liver volume may not necessarily reflect RLF. It may be possible to improve the radical resection rate by 
detecting the potential increase of RLF with RLU15 of Tc-99m GSA scintigraphy.
Key words: PTPE, Tc-99m GSA scintigraphy, LU15, future remnant liver, sinusoidal obstructive syndrome, chemo-
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Introduction
Recently, advances in medical technology have led to ac-
tive and aggressive major hepatectomies. However, hepat-
ic failure is still a fatal complication and is seen in 2.5% to 
12.9% of patients [1-3]. Preoperative percutaneous tran-
shepatic portal vein embolisation (PTPE) is known as an 
effective means of preventing hepatic failure by functional 
residual liver hypertrophy and is often performed. How-
ever, a variety of hepatic injuries, such as liver cirrhosis, 
as well as post-systemic chemotherapy, greatly affect the 
outcomes of PTPE. Although morphological computed 
tomography (CT) volumetry has been widely used as an 
easy method of evaluation before and after PTPE, it is not 
suitable for accurately measuring functional residual liver 
volume.
Norifumi Kennoki, Kiyoshi Koizumi, Koichi Tomita et al.  
e544 © Pol J Radiol 2018; 83: e543-e553
To date, the usefulness of Tc-99m galactosyl human 
serum albumin (GSA) scintigraphy for more accurate 
evaluation of underlying liver diseases, such as cirrhosis 
[4,5], during both the preoperative [2,3,6] and peri-PTPE 
period [7,8], have been reported. A variety of radionuclide 
parameters can be used for Tc-99m GSA scintigraphy, de-
pending on the institute. Residual liver uptake at 15 min-
utes (RLU15), which was reported by Koizumi et al., is 
the cumulative residual liver accumulation rate of a GSA 
tracer 15 minutes after its injection, and it indicates resid-
ual liver function [9]. To safely perform hepatectomies, 
it has been reported that the RLU15 should theoretically 
[10] and clinically [2] be 13 or more. A co-author of the 
present manuscript has already reported the usefulness 
of using RLU15 to predict liver failure [2]; however, to 
date, there has been no evaluation of the effectiveness of 
PTPE using RLU15. We report herein a correlation be-
tween morphological residual liver volume (RLV) and 
RLU15 before and after PTPE in 20 patients, and also 
compare the rate of increase in RLV and RLU15 between 
two groups, diagnosed and evaluated as having pathologi-
cal cirrhosis vs. non-cirrhosis, and post-chemotherapy vs. 
non-chemotherapy.
Material and methods
Patient characteristics and underlying liver disease
Patient characteristics are listed in Table 1. Between Au-
gust 2010 and December 2016, 30 patients underwent 
preoperative PTPE. Ten of them were excluded because 
data on either contrast-enhanced computed tomography 
(CECT) or Tc-99m GSA scintigraphy were missing, and 
therefore 20 patients (14 men and six women, median age: 
72 years, range 42-78 years) were selected as subjects for 
the present study. Six patients were diagnosed as having 
Table 1. Patient characteristics
Patient 
no.
Age
 (years)/Sex
Diagnosis Embolised
portal vein 
branch
Underlying liver disease Interval to follow-up imaging 
from PTPE procedure (days)
Pathological 
cirrhosis 
and fibrotic grade
Chemotherapy, type 
(no. of cycles), 
and pathological findings
To CECT To Tc-99m GSA 
scintigraphy
1 71/M HCC Right No No 22 22
2 77/M MT Right No No* 27 48
3 73/M CC Right No No 13 14
4 61/M HCC Right Yes, 3 No 21 21
5 74/M CC Right No No 21 20
6 64/M HCC Right Yes, 4 No 24 25
7 42/F MT Right No Yes, O (6), mild CASH 17 17
8 70/F MT Right No Yes, O+I (2), mild SOS 21 18
9 76/M HCC Right No No 25 29
10 49/M MT Right No Yes, O (6), moderate CASH 27 27
11 68/M MT Right No Yes, O (6), moderate SOS 18 17
12 72/M CC Right No No 18 20
13 72/F CC Right Yes, 3 No 7 17
14 72/M CC Right No No 21 15
15 72/F CC Left + Ante − No 17 17
16 78/M CC Left + Ante No No 52 25
17 79/M HCC Left + Ante − No 23 23
18 75/F CC Right − No 25 25
19 73/M HCC Post + P4 No No 28 28
20 77/F MT Right No Yes, O (4), moderate SOS 13 13
Median 72 21.0 20.5
HCC – hepatocellular carcinoma; CC – cholangiocarcinoma; MT – metastasis from colorectal cancer; Ante – Anterior; Post – Posterior; P4 – portal vein into segment 4; CECT – contrast-enhanced 
computed tomography; PTPE – percutaneous transhepatic portal vein embolization; O – oxaliplatin-based chemotherapy; O+I – irinotecan-based chemotherapy followed by oxaliplatin-based 
chemotherapy; CASH – chemotherapy-associated steatohepatitis; SOS – sinusoidal obstructive syndrome
*Heterochronous metastasis was detected and the patient did not receive systemic chemotherapy before PTPE. The other patients with MT all had homochronous metastasis and received systemic 
chemotherapy before PTPE.
 Portal vein embolisation evaluated by Tc-99m GSA scintigraphy
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hepatocellular carcinoma (HCC), six were diagnosed as 
having cholangiocarcinoma, and eight were diagnosed 
as having metastases from colorectal cancer (MT). Five 
out of six MT patients underwent systemic chemotherapy 
before PTPE.
Interventional radiology devices and embolic agents
A 6-Fr long sheath and a J-curved and loop-shaped 5.5-Fr 
balloon catheter (Selecon MP catheter II, Terumo, Tokyo, 
Japan) were used in every procedure (Figure 1). Abso-
lute ethanol (Absolute EthanolTM, FUSO Pharmaceutical 
Industries, Ltd., Osaka, Japan) was used as an embolic 
material in all cases and was also used for the ethanol-li-
piodol mixture, which contained 2 ml of ethiodised oil 
(LipiodolTM, Guerbet Japan, Tokyo, Japan) and 8 ml of 
ethanol. The maximum dose of ethanol was decided to 
be less than 0.2 ml/kg of body weight, which was consid-
ered a safe dose. Gelatine sponges (GS, SerescueTM Nippon 
Kayaku Co., Ltd., Tokyo, Japan) were used for approach 
tract embolisation.
PTPE procedure
A routine method by which we perform embolisation 
of the portal vein branch of the right hepatic lobe is de-
scribed below, which is similar to the PTPE outline using 
absolute ethanol reported by Satake et al. [11]. In all cas-
es, the percutaneous transhepatic and ipsilateral approach 
was used. The portal vein of segment no. 5 (P5) or P6 was 
usually punctured with a 21-G needle under ultrasound 
guidance. A 6-Fr long sheath and a 5.5-Fr loop-shaped 
balloon catheter was coaxially inserted and advanced to 
the main trunk of the portal vein. Digital subtraction an-
giography (DSA) was performed, and whole portal vein 
images were confirmed (Figure 2A). A loop was made at 
the tip of the balloon catheter within the splenic vein. The 
tip of the catheter was inserted into the anterior branch 
of the portal vein and the balloon was inflated at the be-
ginning of the anterior branch. Selective DSA was per-
formed from this point (Figure 2B), which was also a test 
injection. The ethanol and lipiodol mixture was carefully 
and slowly injected to avoid backflow, particularly back 
into the left portal branch (Figure 2C). The dose of the 
embolic material was set at approximately the same as that 
of the test injection. Next, a 10-minute wait was necessary, 
until the endothelium of the portal vein became damaged 
and an embolic effect appeared. The balloon catheter was 
removed, DSA was performed from the sheath, and we 
confirmed that the embolised anterior branch of the por-
tal vein was not displayed on the image. Next, the other 
J-curved balloon catheter was inserted into the portal vein 
trunk, and the tip of the balloon was placed on the begin-
ning of the posterior branch as distally as possible because 
this makes portal vein reconstruction easier for the sur-
geon during hepatectomy. Selective DSA (test injection) 
was performed during balloon occlusion (Figure 2D). The 
ethanol-lipiodol mixture was injected from the sheath at 
the same dose as the test injection (Figure 2E). Finally, 
access tract embolisation was necessary to prevent bleed-
ing from the puncture site (Figure 3). A GS was cut into 
equal-sized thin strips, which were rounded into a cylin-
drical shape (Figure 3C). A second sheath was prepared 
and cut at approximately 5 cm intervals (Figure 3D), and 
the cylindrical shaped GS was put into the cylindrical cut 
sheath. The cut sheath within the GS was inserted from 
behind of the first sheath, and the GS was pushed into the 
tract by the inner cylinder with a guidewire from behind 
the first sheath, and the tract was packed with GS in the 
form of a mould (Figure 3E).
Parameters and evaluation items
Before and approximately three weeks after PTPE, CECT 
and Tc-99m GSA scintigraphy were performed. The RLV 
and the RLU15 were used as the main parameter. CT vol-
umetry, including RLV, was calculated by Synapse Vincent 
(Fujifilm Holdings Corporation, Tokyo, Japan). Liver up-
take at 15 minutes (LU15) is the ratio of cumulative liver 
uptake from 15 to 16 minutes after GSA administration di-
vided by the total GSA dose, and its formula is as below [9].
LU15 = × 100 (%)
∫ C(t) dt1615
total injected dose
C (t) is the time-activity curves in which the region 
of interest is set in the liver in a continuous image taken 
from the anterior surface. RLU15 is the value obtained 
by multiplying LU15 by the residual count ratio calculat-
ed from single-photon emission computed tomography. 
Figure 1. Photographs of the balloon catheters that were used. The size of 
the catheters was 5.5 Fr, and 2 types of tips, namely J-shaped and loop-
shaped, were used
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When evaluating residual liver function before hepatec-
tomy, the desirable RLU15 value is reported to be more 
than 13 [10].
As the primary endpoint, RLV, RLU15, the fold change 
in RLV (DRLV), the fold change in RLU15 (DRLU15), and 
correlation between DRLV and DRLU15 were obtained. 
DRLV and DRLU 15 were calculated as follows:
DRLV = , DRLU15 =after RLV after RLU15before RLV before RLU15
The samples of 16 patients who underwent radical 
hepatectomy were histopathologically evaluated. The liver 
cirrhosis group was defined as cases of fibrosis grade (F) 
3 or F4 pathologically diagnosed according to the classifi-
cation reported by Desmet et al. [12].
Sinusoidal obstructive syndrome (SOS) and chemo-
therapy-associated steatohepatitis (CASH) are well-
known hepatic impairments caused by systemic chemo-
therapy for colorectal cancer, and they were evaluated 
Figure 2. Digital subtraction angiography (DSA) during the percutaneous transhepatic portal vein embolisation (PTPE) procedure. A) The tip of the sheath 
was placed on the trunk of the portal vein, and contrast material was injected into the liver. The entire portal vein trunk and branches were displayed. 
B) A loop-shaped balloon catheter was turned back at the splenic vein and then its tip was inserted into the anterior segment branch, and after balloon 
occlusion, DSA of the anterior segment branch was performed. C) The ethanol-lipiodol mixture was carefully injected into the anterior segment branch while 
confirming the absence of reflux. D) A J-shaped balloon catheter was inserted into the beginning of the posterior branch, the balloon was occluded, and the 
contrast material was injected from the sheath. E) The ethanol-lipiodol mixture was carefully injected into the posterior segment branch while confirming 
the absence of reflux. F) In the final image, the portal vein of the right lobe was completely embolised, and only the portal vein of the left lobe was visualised
A
E
C
B
F
D
 Portal vein embolisation evaluated by Tc-99m GSA scintigraphy
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based on the scores reported by Rubbia-Brandt et al. [13]. 
DRLV and DRLU15 were compared between the two 
groups, i.e. the cirrhosis group (n = 3) vs. the non-cirrho-
sis group (n = 13), and the chemotherapy group (n = 5) vs. 
the non-chemotherapy group (n = 15).
As a secondary endpoint, % future remnant liver (FRL) 
change rates (increase %FRL) were calculated using the 
following formulas:
×100%, D%FRL =FRLV after %FRL – before %FRL
TLV–TV before %FRL
%FRL =
(FRLV – future remnant liver volume; TLV – total liv-
er volume; TV – tumour volume)
Adverse events were evaluated using CTCAE v4.0 
software.
Statistical analysis
Ratios were expressed as means and standard deviations. 
For the differences in increases in RLV and RLU15 before 
and after PTPE, Student’s t-test was used. For two-group 
Figure 3. Photographs demonstrating tract embolisation. A) The percutaneous transhepatic tract (arrows) is embolised to prevent bleeding from the 
puncture site. B) A gelatine sponge (GS) and a sharp disposable pointed scalpel. C) The GS was cut into 2-mm rectangular strips and manually rounded 
into a cylindrical shape. D) A new sheath was divided into three equal parts of about 5 cm (arrows), and the cut GS was put into the cut sheath. The GS was 
soaked with a small amount of contrast agent. E) This cut sheath (black arrow) was inserted into the first sheath (white arrow) and pushed with the inner 
tube (white arrowhead) under fluoroscopy. F) The tract was embolised completely in the shape of the mould (arrows)
E F
C D
BA
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comparisons, Wilcoxon’s rank sum test was used. A p-val-
ue less than 0.05 was considered to indicate a significant 
difference between two groups.
Results
The median amount of ethanol used was 7.5 (3.67-10.0) 
ml. The embolic areas were the right lobe in 16 patients 
and the three segments in four patients. Of these four pa-
tients three were embolised in the left lobe and anterior 
segment, and one was embolised in the right lobe and 
segment 4. The median intervals from PTPE to CECT, to 
Tc-99m GSA scintigraphy, and to surgery were 21 (7-52) 
days, 21 (13-48) days, and 31 (20-56) days, respectively. 
Radical resection was performed in 16 patients (curative 
hepatectomy rate: 80%), and these patients were patho-
logically evaluated. In the other four patients (nos. 15, 17, 
18, and 19), hepatectomy was not performed because the 
progression of the original disease was seen (Table 2).
Primary endpoint
Total liver volume before and after PTPE were 1304 ± 278 
ml and 1249 ± 254 ml, respectively, and no significant 
difference was seen (p = 0.53). A significant increase 
was observed in the RLV (464 ± 99 ml and 573 ± 118 ml, 
p = 0.004, Figure 4) before and after PTPE. DRLV in all 
cases was 1.25 ± 0.15. Total liver LU15 before and af-
ter PTPE were 28.8 ± 4.9% and 27.3 ± 4.9%, respective-
ly, which indicated no significant difference (p = 0.35). 
The RLU 15 before and after PTPE were 11.0 ± 2.9% 
and 17.7 ± 3.8%, respectively, with a significant increase 
(p = 5 × 10-7, Figure 4). DRLU15 in all cases was 1.66 ± 0.33. 
No significant correlation was observed in either RLV or 
RLU15 before and after PTPE (r = 0.14, p = 0.66, Figu- 
re 5A), although both RLV and RLU15 were significantly 
increased. Outliers were patients nos. 3, 9, and 16, and 
after these patients were excluded, the correlation coeffi-
cient increased to 0.76 (p = 0.005, Figure 5B). The results 
Table 2. Morphological and functional parameters obtained from PTPE, PTPE complications, and follow-up
Patient 
no.
RLV (ml) RLU15 (%) Complications Radical 
resection*
Reason that radical 
resection 
could not be performed
Before 
PTPE
After 
PTPE
DRLV Before 
PTPE
After
PTPE
DRLU15
1 418 516 1.23 8.5 14.2 1.67 − Yes −
2 501 598 1.19 9.8 17.6 1.80 − Yes −
3 378 360 0.95 5.9 11.4 1.93 − Yes −
4 541 693 1.28 11.0 19.4 1.76 − Yes −
5 459 562 1.22 4.3 7.6 1.77 − Yes −
6 481 675 1.40 10.6 16.8 1.58 − Yes −
7 519 625 1.20 16.5 22.9 1.39 − Yes −
8 313 470 1.50 7.5 18.0 2.40 − Yes −
9 553 633 1.14 10.3 22.9 2.22 − Yes −
10 558 748 1.36 10.9 17.2 1.58 ALT and AST 
elevation 
(grade 4)
Yes −
11 612 637 1.04 13.6 17.3 1.27 − Yes −
12 687 845 1.23 10.3 18.6 1.61 − Yes −
13 495 616 1.24 11.0 22.0 1.69 − Yes −
14 445 609 1.37 12.2 22.0 1.80 − No Multiple dissemination
15 406 484 1.19 13.0 16.7 1.28 − Yes −
16 391 592 1.51 14.7 15.0 1.02 Cholangitis 
(grade 3)
No Tumour progression
17 509 492 0.97 12.7 15.2 1.20 − No Tumour progression
18 358 456 1.27 14.8 21.9 1.48 − No Tumour progression
19 297 411 1.38 10.1 18.8 1.86 − Yes −
20 348 437 1.26 11.9 23.9 1.93 − Yes −
Mean 464 ± 99 573 ± 118 1.25 ± 0.15 11.0 ± 2.9 17.7 ± 3.8 1.66 ± 0.33
PTPE – percutaneous transhepatic portal vein embolisation; RLV – residual liver volume; RLU15 – residual liver uptake at 15 minutes
 Portal vein embolisation evaluated by Tc-99m GSA scintigraphy
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of these three outliers are shown in Table 3. In patients 
nos. 3 and 9 there was a minimal increase in RLV and 
a large increase in RLU15, and these two patients were 
able to undergo radical hepatectomy after PTPE. Patient 
no. 16 showed a large increase in RLV and a small increase 
Figure 4. Changes in residual liver volume (RLV) and residual liver uptake at 15 minutes (RLU15) before and after PTPE. The RLV (before: 464 ± 99 ml; after: 
573 ± 118 ml, p = 0.004) and RLU 15 (before: 11.0 ± 2.9%; after: 17.7 ± 3.8%, p = 5 × 10-7) were significantly increased after PTPE
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Figure 5. Correlation between rates of changes in RLV and RLU15. A) When all patients were analysed, no correlation was observed (r = 0.14, p = 0.66). The 
three outliers were patients nos. 3, 9, and 16 (arrows). B) When the three outliers were excluded, a positive correlation was obtained (r = 0.76, p < 0.005)
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in RLU15, and radical hepatectomy could not be complet-
ed because of tumour progression. The outcomes of the 
two-group comparisons are listed in Table 4. Pathological 
cirrhosis was observed in patients nos. 5, 7, and 14 (Fig-
ure 6A), and the other 13 patients, including those with 
Table 3. Outliers of the RLV and RLU15 results
Patient no. DRLV DRLU15 Outcomes
Outliers of the RLV results 3 0.95 1.93 Radical hepatectomy was performed
9 1.14 2.22
An outlier of the RLU15 results 16 1.51 1.02 Progression of the present disease was confirmed during surgery 
and hepatectomy could not be performed
A B
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Table 4. Outcomes of patients with cirrhotic liver vs. non-cirrhotic liver and patients undergoing systemic chemotherapy vs. no systemic chemotherapy 
before PTPE
Cirrhotic (3) vs. non-cirrhotic (13) p-value Chemo (5) vs. no chemo (15) p-value
DRLV 1.28 vs. 1.22 0.12 1.26 vs. 1.23 0.76
DRLU15 1.69 vs. 1.77 0.59 1.58 vs. 1.69 0.97
Figure 6. Photographs of liver pathology of three representative patients. 
All samples were stained with haematoxylin and eosin; original magnifi-
cation: ×40. The sample in (A) was prepared for the evaluation of fibrotic 
grade, and (B) and (C) were prepared to evaluate post-chemotherapeutic 
effects. A) Patient no. 6 was evaluated as fibrosis grade 4. B) Patient no. 
10 underwent six courses of FOLFOX with Bevacizumab and was concluded 
to have moderate CASH (stenosis in 30% of hepatocytes). C) Patient no. 
20 received four courses of FOLFOX with Bevacizumab and was concluded to 
have moderate SOS (centrilobular involvement of two-thirds of the lobular 
surface)
A
C
B
HCC, had no obvious fibrosis. There were no significant 
differences between cirrhotic and non-cirrhotic groups re-
garding both DRLV (1.28 vs. 1.22, p = 0.12) and DRLU15 
(1.69 vs. 1.77, p = 0.59). Five patients (nos. 7, 8, 10, 11, and 
20) underwent two to six courses of systemic chemother-
apy before PTPE. Oxaliplatin-based chemotherapy was 
performed in these five patients. Only one patient (no. 8) 
switched to irinotecan-based chemotherapy because of an 
allergy to oxaliplatin (Table 1). No significant differences 
were observed between chemotherapy and non-chemo-
therapy groups in both DRLV (1.26 vs. 1.23, p = 0.76) and 
DRLU 15 (1.58 vs. 1.69, p = 0.97).
Secondary endpoint
The % FRL increase was 34.4 ± 25.2%. At the time of in-
jection of ethanol, local abdominal pain was recognised 
in all patients; however, it was under self-control by the 
administration of analgesics. Major adverse events are list-
ed in Table 2. Grade 3 cholangitis, which requires endo-
scopic retrograde biliary drainage (ERBD), was found in 
one patient. Grade 4 alanine aminotransferase (ALT) and 
aspartate transaminase (AST) elevation were observed in 
one patient, grade 3 ALT elevation in 10 patients, grade 
3 AST elevation in seven patients, grade 3 bilirubin eleva-
tion in one patient, and grade 3 thrombocytopenia in one 
patient; however, these symptoms were adequately treat-
ed by conservative treatments. Regarding postembolic 
syndromes, grade 1 fever was observed in five patients, 
grade 2 nausea in five patients, and grade 1 vomiting in 
one patient.
Discussion
Some studies have compared morphological RLV with 
residual liver function (RLF), which is another radionu-
 Portal vein embolisation evaluated by Tc-99m GSA scintigraphy
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clide parameter that is different from RLU15 obtained 
from Tc-99m GSA scintigraphy, before and after PTPE 
[7,8,14]. The fold change in RLV and RLF were 1.28 to 
1.32 and 1.63 to 1.7, respectively, and generally, the in-
crease in the rate of change in RLF is known to be much 
greater than that of RLV [3,6,8,15]. In the present study, 
the fold changes in RLV and RLU15 were 1.25 ± 0.15 and 
1.66 ± 0.33, respectively, which is equivalent to those of 
previous reports. No correlation was seen between the 
fold change in RLV and RLU15 in all patients. Kono et al. 
reported that no correlation was observed between mor-
phological RLV and residual liver R max (a radionuclide 
parameter) before and after PTPE in all patients (r = 0.105, 
p = 0.803) [8]. A good correlation between these parame-
ters was observed when the patients were narrowed down 
to the good response group that showed a large increase 
in R max (r = 0.826, p = 0.037). Nanashima et al. found 
a good correlation between CT volumetry before PTPE 
and RI volumetry (r = 0.69); however, a very weak correla-
tion was found between CT volumetry and RI volumetry 
after PTPE (r = 0.03) [15]. From these previous reports, 
it is suggested that although PTPE increases both RLV 
and RLF, these parameters may not be simply well cor-
related. Therefore, it is clinically important and desirable 
to analyse both parameters for more accurate evaluation 
of liver function. We divided the outliers into two types. 
Type A, comprising two of the three outliers, showed 
a small increase in RLV but a large increase in RLU15 
(Table 3A). Type B, comprising one of the three outliers, 
showed a large increase in RLV but a small increase in 
RLU15 (Table 3B). Compared with morphological RLV, 
RLF values obtained from GSA scintigraphy are known to 
be better correlated with postoperative albumin level [15], 
prothrombin time [10], total bilirubin [10,15], preopera-
tive indocyanine green retention rate at 15 min (ICGR 15) 
[9,10], and postoperative indocyanine green [6,15]. There-
fore, in patients of type A, even if only a small increase 
in RLV is observed, a large increase in RLU15 is likely 
to indicate sufficient regeneration of the residual liver. As 
a result, we were able to perform surgery on all type A pa-
tients. On the other hand, in type B, two hypotheses were 
clinically inferred. The first hypothesis was that the un-
derlying liver disease was much worse, and liver regener-
ation might take a comparatively long time. The remnant 
liver is known to continue to undergo hypertrophy after 
PTPE and postoperatively [3,15]. The second hypothesis 
was that there was rapid progression of the present liver 
disease and that regeneration itself was poor. In the case 
of patient no. 16, the latter hypothesis was thought to be 
true because progression of the present disease was found 
during surgery and hence curative operation was not per-
formed. Many studies have reported that sufficient RLV 
and RLF increases in patients with liver cirrhosis may not 
be observed after PTPE [3,16-19]. In the present study, the 
fold change in RLV appeared to be good (1.28), but the 
RLU15 remained at 1.69. In the case of cirrhotic patients, 
Kono et al. speculated that an increase in RLV reflects not 
an increase in the number of functional hepatocytes but 
instead an increase in the interstitial area [8]. This hypoth-
esis suggests that in patients with liver cirrhosis, even if 
a good increase in RLV is observed, careful evaluation is 
required. To our knowledge, there are few studies com-
paring RLF in post-chemotherapy and non-chemotherapy 
groups before and after PTPE. Patients undergoing sys-
temic chemotherapy after PTPE did not show a significant 
decrease in the rate of increase in RLV compared with 
the non-chemotherapy group [17,20,21]. On the other 
hand, de Baere et al. found that the rate of increase in 
RLV significantly decreased in the patient group, using the 
platinum formulation [22]. Narita et al. reported that the 
rate of increase in RLV significantly decreased in the SOS 
group (16.8 ± 24.0 vs. 55.6 ± 32.5, p < 0.001) [23]. The me-
dian number of chemotherapy cycles was 10 (range, 2-44), 
and the grades of SOS were mild in five patients, moderate 
in four patients, and severe in two patients. Ninety per 
cent of the patients with SOS received more than six cy-
cles of chemotherapy and/or underwent oxaliplatin-based 
chemotherapy. In the present study, the chemotherapy 
group had equivalent outcomes in both RLV and RLU15 
compared with the non-chemotherapy group, and conse-
quently, curative hepatectomy was performed. Five cases 
in the chemotherapy group were pathologically evaluat-
ed, as follows: Moderate SOS was found in patients nos. 
11 and 20, mild SOS in patient no. 8, moderate CASH 
was seen in patient no. 10, and mild CASH was seen in 
patient no. 7. No severe cases of both SOS and CASH were 
observed. An insufficient increase in RLU15 was observed 
only in patient no. 11. Thus, for up to six cycles of chemo-
therapy, it seems that systemic chemotherapy before PTPE 
might not affect increases in RLV and RLU15.
According to a systematic review of PTPE, % FRL was 
used for calculating the hypertrophy response of residual 
liver in 68.2% of reported studies [17]. The average and 
width of % FRL volume increase were used in 37.9 ± 0.1% 
and 20.5% to 69.4%, respectively. Sakuhara et al. report-
ed that, in a study of 143 patients who underwent PTPE 
using ethanol, the % FRL volume increase and resection 
rate were 33.6% and 84%, respectively [24]. In the present 
study, the % FRL volume increase and resection rate were 
34.4 ± 25.2% and 80%, respectively, which were similar to 
the previous study. The rate of PTPE complications was 
reported as 2.2% to 15% [25-27]. As a mild complication 
that is specific to the use of ethanol, pain at the time of 
injection may be reported. However, in our present study, 
most cases of pain were relieved within a few minutes 
with or without analgesics, similarly to a previous pub-
lication [24]. Pneumothorax, cholangitis, PVT, etc. were 
reported as major complications [25-27]. Rare but fatal 
cases of pulmonary embolism and cholangitis after PTPE 
have been reported [28]. In the present study, patient no. 
16 had cholangitis on day 12 after PTPE, and although 
ERBD had been performed 14 days before PTPE, it was 
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performed again. Radical hepatectomy was attempted af-
ter two months; however, the tumour was unresectable 
due to tumour progression. A serious complication after 
PTPE was only observed in this patient.
Limitations
This study has several limitations. Firstly, it is a retro-
spective study with only a few patients. All pathological 
specimens were obtained after surgery, and therefore they 
were affected by both PTPE and surgery. As hypertrophy 
of the residual liver continues even after hepatectomy, 
the final postoperative residual liver function was not 
evaluated. The outcomes after hepatectomy appear to 
most greatly affect the patients’ prognosis; however, the 
success rate of the operation depends not only on resid-
ual liver function but also on operation time, amount of 
bleeding, and whether or not vascular reconstruction was 
performed. In the present study, the effect of pure PTPE 
was evaluated.
Conclusions
No correlation was found between rates of changes in RLV 
and RLU15 both before and after PTPE. Outliers in which 
RLU15 increased despite a small increase in RLV suggest-
ed that these may be cases in which to consider surgery. 
Severe liver injury did not occur upon systemic chemo-
therapy for up to six cycles, and the effects of PTPE were 
similar to those in patients with liver cancer, who did not 
receive chemotherapy.
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